Current Approach to the Diagnosis and Treatment of Heterozygote and Homozygous FH Children and Adolescents
Authors:
Open Access
- 8 May 2021
- journal article
- review article
- Published by Springer Nature in Current Atherosclerosis Reports
- Vol. 23 (6) , 1-14
Abstract
Purpose of Review: To elucidate the current approach of care in pediatric patients with familial hypercholesterolemia (FH). We sought an answer to the question whether the advances and major changes in lipid management are relevant and apply to children and adolescents. Recent Findings: Latest research findings clearly demonstrate that lowering cholesterol levels at a young age prevents vascular atherosclerotic changes and decreases cardiovascular events in adulthood and emphasizes the importance of early detection and intervention in the pediatric FH patients group. Summary: FH is a common genetic disease caused by mutations in genes associated with the metabolism of low-density lipoproteins (LDL). The hallmark of FH is elevated LDL cholesterol (LDL-C) levels from birth and premature atherosclerotic cardiovascular disease (ASCVD). Often FH is either undiagnosed or diagnosed with a considerable delay, leading to vascular atherosclerotic changes and cardiovascular disease. Prompt identification of FH subjects is essential, to initiate early preventive measures. Safe and efficient pharmacological agents are approved for use in children and adolescents. Statins are the first line of therapy, in combination of ezetimibe. Unfortunately, these drugs do not warrant the achievement of therapeutic target, especially in HoFH patient. In the latter, lipoprotein apheresis (LA), which has been shown to be safe and effective, is strongly recommended. Finally, the new drugs still under study will allow a multimodal customized treatment. Lowering cholesterol levels at a young age hinders vascular atherosclerotic changes decreasing cardiovascular events in adulthood. Therefore, early detection, diagnosis, and intervention in FH patients are priority objectives.Keywords
Funding Information
- Università degli Studi di Roma La Sapienza
This publication has 77 references indexed in Scilit:
- Reduction in Mortality in Subjects With Homozygous Familial Hypercholesterolemia Associated With Advances in Lipid-Lowering TherapyCirculation, 2011
- Traitement d’une hypercholestérolémie familiale homozygote par LDL-aphérèse chez un enfant de 4 ansArchives de Pédiatrie, 2009
- Aorta and coronary angiographic follow‐up of children with severe hypercholesterolemia treated with low‐density lipoprotein apheresisTransfusion, 2009
- Low Density Lipoprotein Apheresis in Pediatric Patients With Homozygous Familial HypercholesterolemiaTherapeutic Apheresis and Dialysis, 2009
- Efficacy of statins in familial hypercholesterolaemia: a long term cohort studyBMJ, 2008
- Long-Term Safety and Efficacy of Low-Density Lipoprotein Apheresis in Childhood for Homozygous Familial HypercholesterolemiaThe American Journal of Cardiology, 2008
- Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry studyEuropean Heart Journal, 2008
- Mutations in PCSK9 cause autosomal dominant hypercholesterolemiaNature Genetics, 2003
- LDL Apheresis in a Homozygous Familial Hypercholesterolemic Child Aged 4.5Artificial Organs, 1997
- Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular geneticsThe American Journal of Cardiology, 1993